• In early August 2026, Exelixis reported Q2 results showing revenue of US$628.69 million and net income of US$212.05 million, with both metrics higher than a year earlier and earnings per share increasing on a basic and diluted basis.
• Despite this improvement in profitability, Exelixis trimmed its 2026 revenue guidance and filed a US$112 million common stock shelf registration for an ESOP-related offering, highlighting a balance between moderating top-line expectations and ongoing investment in its workforce and growth plans.
• Now we’ll examine how the lowered full-year revenue guidance, despite stronger earnings, reshapes Exelixis’ previously balanced oncology investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Exelixis Investment Narrative Recap

To own Exelixis, you need to believe cabozantinib can fund a transition to a broader oncology portfolio, led by zanzalintinib and other late stage assets. The Q2 beat on earnings alongside slightly lower 2026 revenue guidance does not appear to change the key short term catalyst, the FDA decision on the zanzalintinib colorectal cancer filing by December 2026, nor the main risk of heavy reliance on a single, maturing cabozantinib franchise.

The most relevant update here is the modest cut to full year 2026 revenue guidance to US$2.50 billion to US$2.55 billion, driven by slower neuroendocrine tumor growth. For me, that directly links this quarter’s story to the broader question of how quickly Exelixis can diversify away from cabozantinib, and how much weight investors should put on upcoming zanzalintinib milestones when thinking about future revenue and earnings power.

Yet while guidance only moved slightly, the dependence on cabozantinib and rising 340B exposure is something investors should be aware of as...

Exelixis’ narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029.

Uncover how Exelixis' forecasts yield a $49.65 fair value, a 8% downside to its current price.

Exploring Other Perspectives

The most bullish analysts were assuming revenue near US$3.8 billion and earnings around US$1.5 billion by 2029, which is far more optimistic than consensus and could be tested by this guidance cut and the pipeline concentration risk you have just read about.

Explore 6 other fair value estimates on Exelixis - why the stock might be worth 9% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.